Context reports preliminary Phase 2 data for ONA-XR: 4-month PFS rate of 44% in metastatic breast cancer

Context Therapeutics Inc.

4-month progression-free survival (PFS) rate of 44% in ER+, HER2- metastatic breast cancer patients in SMILE trial.
ONA-XR combined with fulvestrant showed favorable safety and tolerability in second- or third-line setting.
Previously disclosed endometrial cancer data showed 4-month PFS rate of 77% with anastrozole combination.
ELONA Phase 1b/2 trial combining ONA-XR with elacestrant; Phase 1b data expected Q4 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.